Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Atlanta, Georgia


Purpose:

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.


Criteria:

Inclusion Criteria: - Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months - Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months) - Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics Exclusion Criteria: - Patients with history of psychotic disorder with recovery period of at least 3 months - Female patients who are pregnant or nursing - Patients with a known history of mental retardation


NCT ID:

NCT00034892


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Atlanta, Georgia
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.